311 related articles for article (PubMed ID: 11421528)
1. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
6. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
Meikle AW; Arver S; Dobs AS; Adolfsson J; Sanders SW; Middleton RG; Stephenson RA; Hoover DR; Rajaram L; Mazer NA
Urology; 1997 Feb; 49(2):191-6. PubMed ID: 9037280
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
10. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
Svetec DA; Canby ED; Thompson IM; Sabanegh ES
J Urol; 1997 Nov; 158(5):1775-7. PubMed ID: 9334599
[TBL] [Abstract][Full Text] [Related]
11. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
Kang DY; Li HJ
Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
Cunningham GR; Ellenberg SS; Bhasin S; Matsumoto AM; Parsons JK; Preston P; Cauley JA; Gill TM; Swerdloff RS; Wang C; Ensrud KE; Lewis CE; Pahor M; Crandall JP; Molitch ME; Cifelli D; Basaria S; Diem SJ; Stephens-Shields AJ; Hou X; Snyder PJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6238-6246. PubMed ID: 31504596
[TBL] [Abstract][Full Text] [Related]
14. Clomiphene citrate: A potential alternative for testosterone therapy in hypogonadal males.
Huijben M; Lock MTWT; de Kemp VF; Beck JJH; De Kort LMO; van Breda HMK
Endocrinol Diabetes Metab; 2023 May; 6(3):e416. PubMed ID: 36998229
[TBL] [Abstract][Full Text] [Related]
15. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
16. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.
Douglas TH; Connelly RR; McLeod DG; Erickson SJ; Barren R; Murphy GP
J Surg Oncol; 1995 Aug; 59(4):246-50. PubMed ID: 7543173
[TBL] [Abstract][Full Text] [Related]
17. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
18. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
[TBL] [Abstract][Full Text] [Related]
19. Characterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels.
Chandrapal JC; Nielson S; Patel DP; Zhang C; Presson AP; Brant WO; Myers JB; Hotaling JM
BJU Int; 2016 Dec; 118(6):994-1000. PubMed ID: 27226135
[TBL] [Abstract][Full Text] [Related]
20. Effects of androgen deficiency and replacement on prostate zonal volumes.
Jin B; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]